Skip to main content
. 2019 Mar 11;7(2):77–90. doi: 10.1093/gastro/goz004

Table 1.

Long-term surgical rates in patients with Crohn’s disease (CD) on biologic therapy

Literature Study period Study design No. of patients Biologic used Rate of surgery Follow-up
Schnitzler et al. (2009) [34] 1994–2007 Retrospective single-center 614 Infliximab 23.5% 55 months (median)
Peyrin-Biroulet et al. (2016) [31] 2000–2013 Retrospective multi-center 350 Infliximab or adalimumab 24.9% (calculated 5-year rate) 33 months (median)
Eshuis et al. (2013) [35] 1993–2010 Retrospective multi-center 276* Infliximab 18% no prior surgery for CD; 24% prior surgery for CD 54 months (median)
Alzafir et al. (2011) [36] 2002–2008 Retrospective single-center 71 Infliximab 7% 62 months (median)
Caviglia et al. (2007) [37] 1999–2005 Retrospective single-center 40 Infliximab 20% 27 months (median)
Ljung et al. (2004) [38] 1999–2001 Population-based cohort 191 Infliximab 17.2% 24 months
Feagan et al. (2008) [39] 2000–2002 Randomized–controlled trial 65 Vedoliuzimab 9.2% 24 months
*

Subgroup of patients who underwent maintenance therapy.